cancer

Health compassionate policies including drug-funding policies influence physician practice. Funding policies are especially important in the area of cancer care since cancer is a leading cause of death that is responsible for a significant level of health care expenditures. Recognizing the rising cost of cancer therapies. Cancer compassionate Ontario (CCO) established a funding process to provide access to new effective agents through a "New medicate Funding schedule" (NDFP). The purpose of this chew over is to describe oncologists' perceptions of the impact of NDFP priority setting decisions on their practice. Physician practice is a key determinant of health compassionate outcomes expenditures and quality of care[,]. Health care policies including drug-funding policies have a major influence on physician learn []. However to our knowledge there are no studies of the cause of drug funding policies on oncologist learn. Funding policies are especially important in the area of cancer care for several reasons. Cancer is one of the leading causes of death in Canada. It is estimated that there will be 153,100 new cases of cancer and 70,400 cancer deaths in Canada in 2006[]. Beyond its human toll cancer accounts for 8.3% of health care expenditures in Canada[]. A 1997 chew over estimated that through enjoin and indirect expenditures cancer cost the Canadian economy 13 billion Canadian dollars in 1993[]. The practice of oncologists therefore has a significant cause on the health of Canadians and health care expenditures. In recognition of the rising costs of new cancer drugs. CCO's NDFP was established in 1995 to cover the cost of certain new and expensive IV cancer drugs. The NDFP worked in concert with the CCO Practice Guideline Initiative (CCOPGI) which involves a formal and rigorous process of evidence review knowledge synthesis and consensus development by medical oncology content and methodology experts in Ontario[]. Until 2004 (and at the time of this study) a "Policy Advisory Committee" (consisting of administrators oncologists oncology researchers a pharmacist an ethicist patients and members of the public) made funding recommendations to the NDFP based on a rigorous review of learn guidelines from the CCOPGI and their assessment of the quality of evidence benefits observed and costs of the new medications[]. The specific goal of the NDFP was to ensure equitable access for patients to newly available systemic cancer treatments that have been proven to be effective for their instruct as stated in CCO Practice Guidelines. The schedule reimburses hospitals and cancer centres for drugs administered to patients who meet specific eligibility criteria. This program has grown from a $7 million Canadian dollars program funding 6 drugs for 2354 patients in 1997/98 to a $64 million Canadian dollars program funding 16 drugs for over 14,000 patients in 2003/04. Although the process and rationales used for these decisions have been studied in detail [] the impact of these policies on medical oncologists' practice has not been studied. The purpose of this study is to describe medical oncologists' perceptions of how priority setting decisions for new cancer drugs affected their practice. Medical oncologists from across Ontario in a variety of learn settings. There were approximately 140 medical oncologists in Ontario at the measure of the study. Medical oncologists were identified from publicly available sources (College of Physicians and Surgeons of Ontario website and the Canadian Medical Directory). Purposive sampling targeted oncologists who had been practicing for at least 5 years were so that they were able to comment on their learn before and after the advent of the NDFP. Participants were identified from a variety of practice settings: i e comprehensive cancer centres command hospitals and from both small and large centres. In-depth semi-structured open-ended interviews were conducted with 46 oncologists (for demographic information see delay ) in person or by telecommunicate and were audiotaped and transcribed. Participants were asked to exposit how CCO's NDFP decisions have affected their practice. The interviewers pursued and clarified information about emerging themes. Interviews continued until themes were "saturated" (ie no further new concepts were emerging from interviews.). An initial interview guide was developed (appendix 1) and as is typical in qualitative research was revised during the chew over to investigate emerging themes. Data analysis proceeded concurrently with data collection. Interview transcripts were read and participants' views regarding the impact of drug funding decisions on their learn were identified and coded. Coded units were labelled as specific concepts relating to force on practice. Codes were continuously compared within and between transcripts to verify consistency and comprehensiveness. Similar concepts were grouped together under overarching themes and the data were recoded by theme. The themes were then organized according to perceived importance which was based on both prevalence and the participants' emphasis. Finally descriptions of the themes were developed using the participants' own words. The trustworthiness of our findings was enhanced in three ways. First three investigators coded the raw data to verify the authenticity of the coding scheme; the final coding scheme was developed by consensus and used for the analysis. back up another investigator familiar with the data participated in developing the interpretation. Third a draft of this cover was endorsed by participants in a "member check." Our key finding is that many of the medical oncologists who participated in this study did not accept limits when policy decisions limit find to cancer drugs they conclude would benefit their patients. Moreover overcoming those limits had a significant impact on oncologists' practice in terms of how they spend their time and energy and their relationship with patients. In the end however the perception of most oncologists is that they get what they evaluate will maintain the quality of patient compassionate. Five key themes emerged from the analysis including: 1. find to medications. 2. Overcoming limits to access. 3. Impact on the physician-patient relationship. 4. Disengagement of clinicians from priority setting process and 5. Quality of care. Verbatim quotes from participants are included for illustration. [The NDFP] has been a great help in terms of treatment of cancer patients... It incorporates some of the learn guidelines into displace so that populate are not using drugs at random that may be very expensive. It has also provided me the opportunity to.. provide these patients with some of the expensive drugs which otherwise our pharmacy would not be able to... So I think it has actually in general improved.. the quality of compassionate.. that we are able to give to our patients However they also expressed significant concern about limits on find to drugs. Some oncologists were concerned that the limitations imposed within the funding guidelines did not allow them the flexibility required to alter treatment decisions for individual patients. Others felt that there was often a significant time-lag between demonstration of a drug's efficacy and a funding decision by the NDFP although participants felt that this was improving over time: And so – and in many ways it's restricted our ability to use these drugs more than existed before the program existed. ... I find it very decrease.. certain categories of patients that can be come up defined. But there are also patients who don't fit into the normal situations... The way the CCO schedule is it has very precise indications for drugs. And patients who fall outside those precise indications tough .. We label up the medicate affiliate. We spoke to _____ Hospital. We spoke to CCO. I spoke to _______ of the ______ Disease Site Group. We then called the company; we called two MPP's and we called the third-party insurer from one of the patients who had medicate coverage If the NDFP would not fund the drug they wanted for their patients many physicians would pay considerable time and effort finding an alternate funding source for the drug. The alternate funding sources were quite varied and included enrolling a patient on a clinical trial if they were eligible getting the local hospital to pay for the drug appealing to another government funding program for non-IV drugs looking for give from local charities using leftover drug supplies from patients who had procured funding for a medicate and "gaming" the system or lying on forms so that patients would fit funding criteria for a medicate. These activities were time-consuming and contributed to the physicians' stress. To decrease the time spent on these matters some participants would delegate tasks associated with seeking alternate funding sources to administrative assistants nurses pharmacists or social workers. Priority setting decisions had a significant impact on discussions oncologists had with their patients including the time spent on discussions with patients moral bother regarding those discussions with patients as well as forcing uncomfortable discussions with patients. When a drug was funded by the NDFP participants felt that less discussion was necessary but there was still significant time needed to address drugs where find was limited. Many participants reported that funding issues led to uncomfortable discussions with patients including angry responses from patients who were told that certain treatment options were not available due to funding constraints. Concern was expressed regarding how these discussions would impact patient believe. One participant explained: Situations where a particular drug was not funded created moral bother for many participants. Some entangle it was important to avoid mentioning funding issues in order to protect patients from added anxiety while others felt that fully informing patients meant that they must explain that certain treatments were not funded. While previous studies have described funding policy development for new and expensive cancer drugs this is the first chew over to exposit oncologists' perceptions of the force of those policies on oncologists' practice. We found that many oncologists do not accept limits to drugs they believe to be necessary for their patients even when the decisions are made by a priority setting committee specifically appointed to alter funding policy decisions. Time and energy spent overcoming those limits have a substantial impact on their learn. In the end however most oncologists realise that the quality of care they give for their patients is maintained – because they do what they can to get the drugs that are not funded. Three previous studies have described priority setting for cancer drugs focusing on the decision making process and reasoning used by priority setting bodies []. While these studies provide important information on priority setting decisions are made our study adds important information about how the priority setting policies that are developed affect physician learn. Oncologists in our study did not be to evaluate limits placed on them by funding policy decisions. One possible reason for this is that they did not accept these limits as being legitimate or fair. Daniels has proposed that limits would be accepted if guided by a process that highlights. "a transparency about the grounds for decisions; appeals to rationales that all can evaluate as relevant to meeting health needs fairly.. and that cerebrate well with the goals of various stakeholders in the many institutional settings where these decisions are made[]." The participants in this study did not conclude engaged with the process used to make priority setting decisions and this may be a major cerebrate for not accepting limits. A previous survey of Canadian oncologists reported that more than 80% of respondents agreed that clinical learn guidelines were good educational tools convenient sources of advice and intended to alter quality of compassionate; only 42% of the oncologists surveyed felt that clinical practice guidelines were intended to cut costs []. Our study suggests that despite the positive attitudes towards practice guidelines which were integral to the NDFP's funding decisions[] efforts to improve oncologists' engagement in funding policy decisions by the NDFP are required. One initial concrete step to improve engagement with clinicians would be ensuring that they know as much as possible about the decision-making processes used for cancer drug funding decisions. Two previous papers[,] have described the strengths of those processes but Singer's[] study reports that the reasoning behind those decisions was not widely publicised outside the committee. exceed publicity about how decisions are made might not only help engage oncologists but also help oncologists understand that the decision makers are sometimes restricted by the evidence based guidelines. On the other hand some oncologists may be unwilling to evaluate any limits on care no be how fair the process. Many of the participants in this study were willing to do whatever was necessary to obtain funding for a drug they felt would be beneficial for their patients. It may be that one of the primary tenets of priority setting – that limits must be set to meet population health needs in the approach of resource constraints – will not be easily accepted by physicians who see themselves solely as patient advocates []. Policy makers will need to consider how they ordain broach with physicians who will not accept limits to accessing drugs change surface if set by an "ideal" decision making body. Three findings from this chew over may conflict and therefore provide a useful starting inform for further exploration. First at least some oncologists believe that at least some priority setting decisions are limiting access to drugs that are necessary for quality care. Second many oncologists appear to be spending a significant amount of measure and energy on administration and negotiation related to accessing drugs in situations where find has been limited by policy makers. Third most oncologists in this study claimed that none of this affected the quality of patient compassionate. This begs several questions: When oncologists want access to drugs that policy makers have restricted are these oncologists alter or wrong? Are 'medically necessary' drugs being restricted and if so is that wrong? Should oncologists be spending their time and energy on getting access to restricted drugs or should this time and energy be directed to patient compassionate? If they spent more measure on patient compassionate would this result in more patients being seen and perhaps reduced waiting lists? Certainly further information from studies accurately quantifying how much time is spent on activities to find unfunded drugs would be useful in informing debates generated by the last two questions. According to our findings priority setting decisions had a significant impact on physician-patient relationships. Communicating with patients effectively about difficult subjects is important to maintain an effective and productive physician-patient relationship. Significant work has been done to back up improve communication about other difficult topics desire end-of-life compassionate []. There are proposed frameworks [] on how to communicate effectively about priority setting decisions and further bring home the bacon in this area is warranted. There are two study limitations to this study. First since this study described the views of a strategically selected assort of oncologists about their practices in response to a specific priority-setting process at a given time the findings may not be generalizable to other physicians in different practice settings. As priority-setting processes create by mental act (as they undergo in Ontario where there is now a greater influence of cost-effectiveness data) further research will be needed to assess how physicians' practice is affected by these processes. back up the physicians in this study shared their of how priority setting decisions affected their practice – this may not coincide with their actual practice. However it is likely that lessons gleaned from this study and the questions it raises can help priority setting decision makers and clinicians who must learn in the aftermath of their decisions. In conclusion this study has shown that when priority setting decisions limit access to cancer medications oncologists' effort to overcome those limits have a significant impact on their learn. Policy makers need to seriously consider the implications of their decisions on physicians who may go to considerable effort to circumvent their policies in the name of patient advocacy. Stacey Hubay participated in the conception and design of the study acquisition analysis and interpretation of data and revising the bind critically for important intellectual content Hagit Soibelman participated in acquisition analysis and interpretation of data and revising the article critically for important intellectual circumscribe Douglas Martin participated in the conception and design of the study analysis and interpretation of data and drafting and revising the article critically for important intellectual content 2. Describe the effect Cancer Care Ontario's New Drug Funding Program has had on your decisions to bring down new cancer chemotherapies. 3. express me about how have you dealt with situations where you wanted to prescribe a drug for a patient but the drug was not funded. How has this changed since the New Drug Funding schedule started funding new drugs? 4. exposit the effect of either Cancer compassionate Ontario's New Drug Funding schedule on discussion of chemotherapy treatment options with patients.

MDM2 is an important contradict regulator of the p53 tumor suppressor protein. A naturally occurring T/G single nucleotide polymorphism (SNP) in the MDM2 gene promoter. SNP309 causes an change magnitude in MDM2 protein levels and impairment of p53 tumor suppressor activity. SNP309 occurs at a relatively high frequency in the general population and has been associated with accelerated tumorigenesis in hereditary Li-Fraumeni associated cancers as well as in sporadic soft tissue sarcomas. The objective of this study was to examine the association between SNP309 and sporadic endometrial cancer risk. The tumor suppressor p53 gene is mutated in minimally half of all cancers. It is therefore reasonable to assume that naturally occurring polymorphic genetic variants in the p53 stress response pathway might determine an individual's susceptibility to cancer. A central node in the p53 pathway is the MDM2 protein a direct contradict regulator of p53. In this report a hit nucleotide polymorphism (SNP309) is found in the MDM2 promoter and is shown to change magnitude the affinity of the transcriptional activator Sp1 resulting in higher levels of MDM2 RNA and protein and the subsequent attenuation of the p53 pathway. In humans. SNP309 is shown to associate with accelerated tumor formation in both hereditary and sporadic cancers. A model is proposed whereby SNP309 serves as a rate-limiting event in carcinogenesis. MDM2 is a phosphoprotein that interacts with P53 and inhibits its activity. Recently a T/G substitution (SNP309) in the promoter of MDM2 was identified and has been demonstrated to be associated with an increased MDM2 expression and a significantly earlier age of onset of several tumors including breast cancer. To test the hypothesis that this functional variant in the MDM2 promoter is associated with risk of breast cancer we conducted a molecular epidemiological study of 366 breast cancer cases (BC). 263 patients with benign breast diseases (BBD) and 605 cancer-free controls in China in which we genotyped this T/G variant and another common insertion/deletion polymorphism (Del1518) in the MDM2 promoter and evaluated the associations between these two polymorphisms and converge cancer risk. We open that the variant allele frequencies of these two polymorphisms were not statistically different between the cases and controls (SNP309G: 0.500. 0.542 and 0.506 in BC. BBD and controls respectively and Del1518−: 0.296. 0.308 and 0.297 in BC. BBD and controls respectively). Logistic.

26/11/2007London. UK; Tokyo. lacquer; 26 November 2007: GW Pharmaceuticals plc (AIM: GWP) and Otsuka Pharmaceutical Co.. Ltd today announced that the first US Phase II/III dose-ranging trial has been initiated to evaluate the efficacy and safety of Sativex® in the treatment of pain in patients with advanced cancer who undergo inadequate analgesia during optimized chronic opioid therapy. The principal investigator of this study is Dr. Russell K. Portenoy. Chairman of the Department of Pain care for and Palliative compassionate at Beth Israel Medical Center in New York City. This five-week placebo-controlled chew over ordain include approximately 40 centers primarily in the US and register a be of 336 patients. Patients enrolled in this study must undergo advanced cancer for which there is no known curative therapy and undergo a clinical diagnosis of cancer-related pain which is not wholly alleviated with their current opioid treatment. The primary objective of the study is to evaluate the potential role and process range of Sativex in these patients as an adjunct to their pre-existing pain medications. The primary endpoint of the study will be the response evaluate for patients at the end of 5 weeks of therapy as defined by a 30% or greater reduction in the 11-point. Numeric Rating measure (NRS). Commenting on the importance of this chew over. Dr. Portenoy said. “Studies declare that more than one-third of patients with cancer and more than three-quarters of those with advanced disease have chronic pain. Large surveys tell that optimal opioid therapy does not yield sufficient relief in a substantial harmonise of these patients. There is a alter be for new treatments to improve these outcomes and it is our hope that cannabinoid formulations may represent an important option in the future. This US-based study is a welcome step in assessing the role of Sativex® as a potential new treatment for cancer hurt."Dr Geoffrey Guy. GW’s Chairman said. “GW has spent many years preparing for the US development of Sativex® and has established change state and positive interactions with relevant federal agencies. The start of the first large scale US clinical trial is a major milestone for the company and for the future prospects for Sativex®. We are delighted to be working in close collaboration with our furnish. Otsuka in advancing Sativex® toward the goal of obtaining US regulatory approval."Dr. Taro Iwamoto. President of Otsuka Pharmaceutical Development and Commercialization. Inc. likewise noted that “Otsuka is very excited to be working with GW Pharmaceuticals for the development of this potential alternative come to the treatment of advanced cancer hurt. The initiation of this US clinical trial for Sativex is consistent with our mission to develop products for exceed health.�Sativex® is an investigational new product composed primarily of two cannabinoids: CBD (cannabidiol,) and THC (delta 9 tetrahydrocannabinol). Sativex® ordain be administered as a metered process oro-mucosal disperse each 100µL disperse contains 2.7mg THC and 2.5mg CBD. The Sativex® formulation is standardized by both composition and dose and is supplied in small spray vials. The components of Sativex have been shown to attach to cannabinoid receptors that are distributed throughout the central nervous system and in immune cells. This arrange II/III dose ranging study will act to replicate and extend data from a previous two-week clinical trial in 177 patients conducted in Europe. In this European chew over. Sativex® was administered to patients with terminal cancer and persistent pain that was not fully relieved by current strong opioid therapy. The primary endpoint of this study was the dress from baseline to endpoint in the NRS hurt score. Sativex as adjunctive treatment to strong opioid therapy was associated with a larger decrease in NRS advance than was placebo and strong opiods (p=0.014). In addition. 43% of patients who received Sativex® while remaining on opioids exhibited at least a 30% decrease in their pain score compared to 21% of patients receiving placebo and opioids (p= 0.024)Treatment related adverse events in this chew over were reported by 85% of patients receiving Sativex and by 75% of patients receiving placebo. The most common adverse events (> 10%) reported by patients in this chew over were somnolence (15% Sativex® vs. 13% placebo); nausea (12% Sativex® vs. 11% placebo) and dizziness (12% Sativex® vs. 5% placebo). Serious adverse events reported by more than one patient receiving Sativex were urinary retention (n=2) and progression of the underlying cancer (n=6). Enquiries:For GW: GW Pharmaceuticals plc Today: +44 20 7831 3113Dr Geoffrey Guy. head Thereafter: + 44 1980 557000Justin Gover. Managing Director Mark Rogerson. Press and PR Tel: + 44 7885 638810 Financial Dynamics Tel: +44 20 7831 3113David Yates. Ben Atwell For Otsuka: US Inquiry Debbie Kaufmann Tel: +1 240 683 3568lacquer Inquiry Hideki Shirai siraih@otsuka jpNotes to EditorsAbout GW-OtsukaOn 14 February 2007. GW and Otsuka entered into a major desire call strategic alliance. The relationship commenced with the signing of an exclusive license agreement to create and market Sativex® GW’s lead product in the US. Under this agreement. GW and Otsuka jointly administer US clinical development and regulatory activities as well as the commercialization strategy. GW is responsible for carrying out the US clinical development program the costs of which are borne by Otsuka. Otsuka ordain be responsible for the marketing and sales activities in the US. On 9 July 2007. GW and Otsuka signed a global research collaboration for the study of cannabinoids in the field of Central Nervous System (CNS) and oncology to research develop and commercialize a range of candidate cannabinoid products. About Otsuka Pharmaceutical Co.. LtdFounded in 1964. Otsuka Pharmaceutical Co.. Ltd is a global healthcare company with the corporate philosophy: 'Otsuka - populate creating new products for exceed health worldwide.' Otsuka researches develops manufactures and markets innovative and original products with a cerebrate on pharmaceutical products for the treatment of diseases and consumer products for the maintenance of everyday health. Otsuka is committed to being a corporation that creates global determine adhering to the high ethical standards required of a company involved in human health and life maintaining a dynamic corporate culture and working in harmony with local communities and the natural environment. The Otsuka Pharmaceutical assort comprises 99 companies and employs approximately 31,000 populate in 17 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned US$7.2 billion in annual revenues in fiscal 2006. Focusing on the central nervous system the circulatory respiratory and digestive systems ophthalmology and dermatology. Otsuka’s pharmaceutical product business engages in the research and development make and sale of pharmaceuticals aiming to maximize the assets of a global network to address unmet medical meets. For additional information visit www otsuka-global comAbout GWGW was founded in 1998 and listed on the AiM a market of the London have transfer in June 2001. Operating under authorise from the UK Home Office the company researches and develops cannabinoid pharmaceutical products that alleviate pain and other neurological symptoms in patients who suffer from serious ailments. GW has assembled a team of over 100 scientists with extensive.

- A walk resistant to cancer even highly-aggressive types has been created by researchers at the University of Kentucky. The breakthrough stems from a discovery by UK College of care for professor of radiation medicine Vivek Rangnekar and a team of researchers who open a tumor-suppressor gene called "Par-4" in the prostate. The researchers discovered that the Par-4 gene kills cancer cells but not normal cells. There are very few molecules that specifically contend against cancer cells giving it a potentially therapeutic application. Funded by several grants from the National Institutes of Health. Rangnekar's study is unique in that mice born with this gene are not developing tumors. The mice grow normally and have no defects. In fact the mice possessing Par-4 actually be a few months longer than the control animals indicating that they have no toxic side effects."We originally discovered Par-4 in the prostate but it's not limited to the prostate. The gene is expressed in every cell type that we've looked at and it induces the death of a broad range of cancer cells including of cover cancer cells in the prostate," said Rangnekar. "The interesting move of this chew over is that this killer gene is selective for killing cancer cells. It ordain not blackball normal cells and there are very very few selective molecules out there desire this."To advance investigate the potential therapeutic benefits of this gene. Rangnekar's aggroup introduced it into the egg of a mouse. That egg was then planted into a surrogate mother."The mouse itself does not convey a large number of copies of this gene but the pups do and then their pups start expressing the gene," Rangnekar said. "So we've been able to transfer this activity to generations in the mouse."The implications for humans could be that through hit the books marrow transplantation the Par-4 molecule could potentially be used to fight cancer cells in patients without the toxic and damaging side effects of chemotherapy and radiation therapy."When a cancer patient goes to the clinic they change chemotherapy or radiation and there are potential align effects associated with these treatments," Rangnekar said. "We got interested in looking for a molecule which will kill cancer cells and not kill normal cells but also would not be toxic with believe to the production of align effects to the entire organism. We are thinking of this in a holistic approach that not only would get rid of the tumor but also not harm the organism as a whole. Before this animal study we published a lot of work indicating that in cell grow there's no killing of normal cells. This is the create that it doesn't blackball normal cells because the walk is alive and healthy."Rangnekar admits there is much more bring home the bacon to be done before this investigate can be applied to humans but agrees that is the most logical next step."I look at this research from the standpoint of how it can be developed to the acquire of the cancer patient and that's really what keeps us focused all this time," said Rangnekar. "If you look at the pain that cancer patients go through not just from the disease but also from the treatment - it's excruciating. If you undergo someone in your family like I did who has gone through that you know you can see that hurt. If you can not only interact the cancer but also not harm the patient that's a major breakthrough. That's happening with these animals and I think that's wonderful." University of Kentucky Researchers from the Abramson Cancer Center of the University of Pennsylvania announced today that findings from two large international clinical trials show unprecedented survival for patients with multiple myeloma a cancer that occurs in the blood-making cells of bone marrow. Findings from two large international clinical trials show "unprecedented" survival for patients with multiple myeloma a blood cancer that occurs in the blood-making cells of bone marrow. Investigators at St. Jude Children's investigate Hospital undergo discovered a new signaling molecule that prevents immune responses from running amok and damaging the body. Recently scientists demonstrated the anti-cancer effects of silibinin a study biologically active compound of draw thistle. Being widely used as a folk remedy for liver diseases milk thistle is safe and well-tolerated and it protects the liver from drug or alcohol-related injury. New investigate suggests that the presence or absence of two proteins may be important markers for long-term survival in some breast-cancer patients. A sophisticated microscope that offers a "real-time" 3-D analysis of create from raw material samples might in the future decrease the number of needle biopsies traditionally needed from women suspected of having breast cancer according to recent research published at Georgetown University Medical Center's Lombardi Comprehensive Cancer Center. A novel compound that blocks the breakdown of retinoic acid derived from vitamin A is a surprisingly effective and "promiscuous" agent in treating animal models of human prostate cancer say investigators from the University of Maryland. Baltimore (UMB). Exposing estrogen-sensitive converge cancer cells to extracts of channel catfish caught in areas with heavy sewer and industrial waste causes the cells to calculate. One way environmental stress causes cancer is by reducing the activity level of an enzyme that causes cell death researchers say. An international aggroup of scientists today announced the results of a systematic effort to map the genetic changes underlying lung cancer the world's leading cause of cancer deaths.

Below is a cerebrate for the trial of BLP25 Lipossomal vaccine (Stimuvax) for non-small cell lung cancerI posted this on my website back in April and at the time the trials had not started. I see that on the site it says they have now begun. It ordain recruit about 1,300 people with re-create 3 non-small cell lung cancer from various countries around the world. BLP25 is a new and experimental and is not licensed as a treatment yet. It is not currently available outside of a clinical trial. An international arrange 3 trial is now open in a number of countries. While this trial is recruiting patients in the UK. It doesn't look like it is available for Mesothelioma at the moment but I would like to find more information about it. If anyone finds anything about this trial please let me know and I will post it here.

Mesothelioma is a form of cancer. It caused by previous exposure to asbestos. An exposure of as little as one or two months can result in mesothelioma 30 or 40 years later. Simian virus 40 (SV40) may act as a cofactor in the development of mesothelioma. Malignant mesothelioma is the most serious of all asbestos-related diseases. The two major types of malignant mesothelioma are pleural mesothelioma which concerns the mesothelium membrane that surrounds the lungs and peritoneal mesothelioma which concerns the mesothelium forge that covers the organs in the abdominal cavity. The populate most at assay from being carriers of this cancer are those have worked with asbestos over the past thirty to fifty years. Because of this the disease is most common in men between the ages of sixty and seventy as this is the assort that commonly worked with asbestos during those years. Because of the lack of protection and regulations in those days these workers were constantly exposed to the dust and fibres from the asbestos which caused the cells of the mesothelium to become abnormal. Many building materials used in both public and domestic premises prior to the banning of asbestos may include asbestos. Those performing renovation works or diy activities may subject themselves to asbestos dust. Mesothelium helps defend the organs by producing a special lubricating fluid that allows organs to act around. Mesothelioma is an extremely malignant and incurable cancer that infects the membrane that surrounds most of the internal organs. Symptoms of mesothelioma may not be until 20 to 50 years after exposure to asbestos. Shortness of breath cough and hurt in the chest due to an accumulation of fluid in the pleural space are often symptoms of pleural mesothelioma. Affecting the mesothelial cells that alter up the mesothelium – the outer lining that protects the be’s study organs such as the heart stomach and lungs. Pleural mesothelioma represents 75% of mesothelioma cases - but it is far from the only write of this deadly cancer. Peritoneal mesothelioma affects the lining around the digest and intestines and is just as dangerous and deadly. Treatment of MM using conventional therapies has not proved successful and patients undergo a median survival measure of 6 - 12 months after presentation. The clinical behaviour of the malignancy is affected by several factors including the continuous mesothelial surface of the pleural cavity Mesothelioma Cancer Treatment and Prevention Tips1. Health-care workers who alter in move control are employing state-of-the art techniques to successfully fight pain.2. During the initial stages of mesothelioma hurt can be relieved with over-the-counter analgesics such as aspirin. Tylenol or ibuprofen (Advil. Motrin).3. Drug therapy is the primary method for treating mesothelioma hurt.4. Non-Opoids are pain-relieving medicines such as acetaminophen (Tylenol) and NSAIDs such as ibuprofin which can be purchases over-the-counter and taken orally.5. Opoids are the strongest medicines available to treat hurt. Opoids such as codeine morphine oxcodone fentany and hydromorphone are very effective in relieving mesothelioma hurt.6. Adjuvant analgesics are medicines intended for purposes other than pain relief. A be of these are used to ameliorate hurt associated with mesothelioma such as antidepressants anticonvulsants and steroids.7. Emotional give to back up ameliorate hurt. As with all aspects of mesothelioma emotional support from family or professional counseling can play a key role in pain management8. For patients with localized disease and who can tolerate a radical surgery radiation is often given post-operatively as a consolidative treatment.9. Chrysotile has been used more frequently hence many mesotheliomas are caused by chrysotile.10. Removal is taking place in schools and other public buildings throughout the U. S. The hope is that these measures will greatly decrease the occurrence of this cancer.

say: The contents of this blog are for informational purposes only and should not be construed as medical advice or substitute for professional care. For medical emergencies dial 911! On Pavarotti and pancreatic cancer Posted Sep 14th 2007 2:31PM by Filed under: . Luciano Pavarotti possibly the most famous classical singer on hide a final sendoff this past weekend in his hometown of Modena. Italy. Pavarotti died measure week of pancreatic cancer. More than 100,000 people filed through the cathedral and plaza more than 700 guests attended the funeral crowd and millions watched the be broadcast on television. Pavarotti underwent surgery for a malignant pancreatic mass in July 2006. A month later after his surgery. Pavarotti the Italian newspaper Corriere della Sera "I was a fortunate and happy man. After that this breathe out arrived. And now I am paying the penalty for this fortune and happiness."One could not be surprised that Pavarotti felt this way. Pancreatic cancer is one of the most deadly cancers with a five-year survival evaluate here in the U. S of less than 5% although surgery can alter survival greatly. Pancreatic cancer is also one of the most research areas in cancer. For more information about what you can do to increase funding for pancreatic cancer research and increase awareness of this deadly disease please see. Please keep your comments relevant to this blog entry. Email addresses are never displayed but they are required to affirm your comments. When you enter your label and telecommunicate address you'll be sent a link to confirm your comment and a password. To get another mention just use that password. To act a live cerebrate simply type the URL (including http://) or email address and we ordain alter it a be link for you. You can put up to 3 URLs in your comments. Line breaks and paragraphs are automatically converted — no need to use <p> or <br> tags. All contents copyright © 2003-2007. All rights reserved is a member of the. Other Weblogs Inc. communicate blogs you might be interested in: